Thromboprophylaxis in Ambulatory Lung Cancer Treatment

Cavaliere, Loretta
February 2013
Clinical Journal of Oncology Nursing;Feb2013, Vol. 17 Issue 1, p74
Academic Journal
Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, are common problems experienced by patients with lung cancer that can impact treatment plans, prognoses, and survival. Patients with lung cancer are at greatest risk for development of VTE in the ambulatory care treatment setting. Literature does exist on VTE management for medical and surgical oncology inpatients, as well as clinical guidelines for inpatient prophylaxis; however, published evidence is lacking on outpatient risk and thromboprophylaxis in medical oncology outpatients, particularly patients with lung cancer. Because patients with lung cancer treated in the ambulatory setting have established risks for VTE, they may benefit from thromboprophylaxis. Clinical guidelines for outpatient thromboprophylaxis direct the clinical practice for thromboprophylaxis in lung cancer treatment. The purpose of the current article is to explore the VTE risks associated with ambulatory lung cancer treatment and to review the recommended guidelines for thromboprophylaxis to guide clinical decision making for patients with lung cancer.


Related Articles

  • Prevention of Venous Thromboembolism in Patients with Hemorrhagic Stroke. Chaudhry, Farrukh S.; Schneck, Michael J.; Morales-Vidal, Sarkis; Javaid, Furqan; Ruland, Sean // Topics in Stroke Rehabilitation;Mar/Apr2013, Vol. 20 Issue 2, p108 

    Deep venous thrombosis (DVT) and pulmonary embolism (PE) are part of the spectrum of venous thromboembolism (VTE). It is one of the most frequent medical complications in stroke patients. The risk of VTE is even higher after hemorrhagic stroke. This article reviews various screening methods,...

  • The incidence of pulmonary embolism during deep vein thrombosis. Nielsen, J. D. // Phlebology;Mar2013 Supplement, Vol. 28, p29 

    Among life-threatening cardiovascular diseases, pulmonary embolism (PE) is the third most common after myocardial infarction and stroke. PE is a manifestation of venous thromboembolism (VTE). PE shares risk factors with deep vein thrombosis (DVT) and is regarded as a consequence of DVT rather...

  • Circulation & SCI.  // PN;Jun2012, Vol. 66 Issue 6, p26 

    The article reports that some long-distance travelers might be at risk of pulmonary embolism (PE) and deep vein thrombosis (DVT) according to the Centers for Disease Control and Prevention (CDC). It says that the changes in the blood pressure and circulation can increase the risk of developing...

  • Secondary prophylaxis with oral anticoagulant therapy.  // American Family Physician;10/1/1995, Vol. 52 Issue 5, p1500 

    Reports on a study from the June 22, 1995 issue of the `New England Journal of Medicine,' by Schulman and colleagues comparing the effectiveness of six weeks of oral anticoagulant therapy with that of six months of therapy for secondary prophylaxis. Results indicating that six months of...

  • Risk assessment and treatment of venous thromboembolism. Rogers, Jean // Emergency Nurse;Dec2010, Vol. 18 Issue 8, p24 

    This article argues that the number of deaths caused by venous thromboembolism (VTE) can be reduced if all patients in emergency departments are assessed to identify those who are most at risk of developing VTE. Such patients can be given the appropriate anticoagulant prophylaxis and educated on...

  • Preventing Deep Venous Thrombosis in Hospitalized Patients. King, Mitchell S. // American Family Physician;5/1/1994, Vol. 49 Issue 6, p1389 

    Presents information on how to prevent pulmonary embolism by preventing the occurrence of deep venous thrombosis. Predisposing factors involved; Effectiveness of various prophylactic treatments; Risk of hemorrhagic complications in the perioperative period; Cost-effectiveness of prophylactic...

  • AMPLIFY trial results. Elliott, William T. // Clinical Cardiology Alert;Sep2013 Pharmacology Watch, p2 

    The article focuses on the results of the AMPLIFY trial which compares the efficacy of apixaban with conventional anticoagulant therapy in acute venous thromboembolism (VTE) patients.

  • AMPLIFY trial results.  // Hospital Medicine Alert;Sep2013 Pharmacology Watch, p2 

    The article discusses research done on the effects of apixaban and anticoagulant therapy in patients with acute venous thromboembolism (VTE) published online in the July 1, 2013 issue of the "New England Journal of Medicine."

  • AMPLIFY trial results.  // Critical Care Alert;Sep2013 Pharmacology Watch, p2 

    The article focuses on the AMPLIFY clinical trial conducted on patients with acute venous thromboembolism (VTE) to compare the effectiveness of conventional anticoagulant therapy with oral anticoagulant apixaban.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics